Scarica l'app Stockscreener
135.77
2.04%
2.71
Dopo l'orario di chiusura:
136.01
0.24
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences stock may move 4.3% on August earnings report By Investing.com - Investing.com South Africa
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Benzinga
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Gilead Sciences Inc (GILD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gilead uses humor, relatability in ‘Up to Date’ HIV prevention push - Fierce Pharma
GILD|Gilead Sciences Inc|Price:131.549|Chg%:+1.029 - TradingKey
Gilead Sciences (GILD) Gets a Hold from RBC Capital - The Globe and Mail
Laverne Cox Presents Gilead With Excellence in Corporate Philanthropy Award | Social Impact Summit - The Hollywood Reporter
Preventing Those Living with HIV from Navigating the Journey Alone: Henrique’s Commitment - Gilead Sciences
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
J&J, Gilead among recipients of EU drug recommendations this week - Seeking Alpha
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Gilead’s Trodelvy gets EU panel backing for breast cancer combo By Investing.com - Investing.com Canada
in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer - Business Wire
EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk - Stock Titan
GILD|Gilead Sciences Inc|Price:129.310|Chg%:-1.550 - TradingKey
Gilead Sciences stock trades steady as HIV and oncology pipeline supports long term growth - AD HOC NEWS
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise? - Yahoo Finance
ETFs Investing in Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Stocks - TradingView
How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention - IMDb
Gilead, Merck weekly HIV pill maintains suppression in Phase III switch studies - The Pharma Letter
Why Is Gilead Sciences (NASDAQ:GILD) Trending on the Nasdaq? - Kalkine Media
[AIDS 2026] [Press release] Gilead & Meck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy - European AIDS Treatment Group
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026 - Yahoo! Finance Canada
Gilead Sciences to release Q2 2026 results on August 4 - scanx.trade
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
Gilead and Merck report weekly HIV trial results - grafa.com
GILD Downgraded by Leerink Partners -- Price Target Lowered to $127 - GuruFocus
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1 - TradingView
Gilead to present HIV prevention and treatment data at AIDS 2026 - Investing.com Canada
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure - Business Wire
Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Moomoo
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More - 24/7 Wall St.
Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… - marketscreener.com
Gilead Sciences stock trades steady as HIV and oncology pipeline supports outlook - Ad-hoc-news.de
Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences (GILD) Downgraded by Leerink Partners Amid Marke - GuruFocus
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Gilead Sciences stock trades steady as HIV and oncology pipeline underpins recent earnings - Ad-hoc-news.de
Gilead Sciences stock trades steady as HIV and oncology portfolio supports earnings trajectory - ad-hoc-news.de
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates - Seeking Alpha
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Gilead Built Its Foundation On HIV; Is It Now In Trouble? - Investor's Business Daily
With Up To Date campaign, Gilead brings HIV prevention into the dating conversation - Medical Marketing and Media
Gilead Sciences synthesizes new KRAS mutant inhibitors - BioWorld News
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock By Investing.com - Investing.com South Africa
Gilead Sciences stock trades steadily as oncology progress and HIV franchise support valuation - ad-hoc-news.de
Form 4 Gilead Sciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock By Investing.com - Investing.com South Africa
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences In - GuruFocus
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock - Investing.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv - GuruFocus
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan - Stock Titan
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):